EyeCon 2026 Banner

News

The FDA has accepted for review a supplemental new drug application submitted by Sirion Therapeutics Inc., which seeks market approval of difluprednate ophthalmic emulsion 0.05% (Durezol) for the treatment of endogenous anterior uveitis, according to a statement issued by Sirion.

iScience Interventional has launched a new surgeon support Web site, called iForum, that can be viewed at www.iforummd.com, according to a release issued by the company.

Bausch & Lomb and Pfizer have entered into a co-promotion agreement that involves both companies? prescription ophthalmic pharmaceuticals in the United States, the companies announced in a joint statement.

Roche and Genentech announced that they have signed a merger agreement in which Roche will acquire the outstanding publicly held shares of Genentech for $95 per share, or $46.8 billion, according to statements issued by both companies.

European Union-Public screenings were scheduled to take place on World Glaucoma day today at a variety of venues including private practices and hospitals in Austria, Belgium, Bulgaria, Greece, Italy, Spain, and Switzerland, in observance of World Glaucoma Day.

London-In observance of World Glaucoma Day (WGD), the Motion Displacement Test (MDT), developed by Moorfields Eye Hospital, London, in partnership with University College London (UCL) Institute of Ophthalmology and City University London was on display as part of a demonstration of the latest glaucoma diagnostic equipment.

Latin America-World Glaucoma Day events occurred across Latin and Central America. In Argentina, Maria Carrasco, MD, of Hospital Perrupato granted radio interviews about glaucoma in Mendoza. Television, radio, and newspaper interviews also were scheduled in San Pedro, Argentina (Jorge Marceillac, MD), Santa Cruz, and Buenos Aires.

Washington, DC-To recognize the second annual World Glaucoma Day (WGD), the Association for Eye and Vision Research (AEVR) sponsored a March 10 Capitol Hill briefing to educate Members of Congress and their staffs.

New York-As president and chief executive officer of the World Glaucoma Foundation, and president of the World Glaucoma Patient Association (WGPA), Scott R. Christensen has been extensively involved in planning and coordinating efforts around the world to raise awareness about the critical need to detect glaucoma in its earliest stages possible.

New York-In observance of the second annual World Glaucoma Day, ambassadors, deputy ambassadors, and the secretary general and his staff at the United Nations headquarters here were invited to a free glaucoma screening Wednesday, which was hosted by the New York Eye and Ear Infirmary and The Glaucoma Foundation.

New York-The World Glaucoma Association and the World Glaucoma Patient Association (WGPA) are teaming up with governmental agencies, health-care providers, eye-care industry members, and others to sponsor the second annual World Glaucoma Day (WGD) today, which is expected to surpass last year's efforts.

New York-To help celebrate the second annual World Glaucoma Day, government representatives, eye-care professionals, patient groups, and members of the industry throughout the world offered their support through specific programs designed to increase global awareness of glaucoma and the importance of early detection and successful management.

San Diego-Intervention can improve patient adherence with once-daily glaucoma therapy, according to results of a randomized clinical trial reported by David S. Friedman, MD, PhD, professor of ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore.

San Diego-The answer to low patient adherence to glaucoma medications may be as simple as improving communication, according to researchers. Harry A. Quigley, MD, of the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, and his colleagues studied physician-patient communication to determine ophthalmologists' proficiency for detecting and dealing with patient non-adherence to medications.

San Diego-A trabecular micro-bypass implant (iStent, Glaukos) helped to reduce IOP effectively in a prospective study of 25 patients. “Multiple [stents] placed in Schlemm’s canal, combined with phacoemulsification, had a significant effect in lowering IOP in this study,” said Ike K. Ahmed, MD, University of Toronto.

San Diego-In the Tube versus Trabeculectomy (TVT) Study, patients undergoing trabeculectomy with mitomycin C (MMC) were more likely to experience early postoperative complications than were those who had tube shunts implanted, but rates of late postoperative complications and serious complications associated with vision loss and/or re-treatment were similar for both surgical procedures, said Donald L. Budenz, MD, MPH, professor of ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine.